Opendata, web and dolomites

PAH-HOPE SIGNED

New hope for the PAH patient: A Novel Therapeutic for Pulmonary Arterial Hypertension (PAH)

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PAH-HOPE project word cloud

Explore the words cloud of the PAH-HOPE project. It provides you a very rough idea of what is the project "PAH-HOPE" about.

independent    commercialization    revenue    therapeutics    untreated    heart    patent    cliff    debilitating    disruptive    physicians    extend    truly    outcomes    treat    securement    700m    treatment    manufacture    15    predicted    company    thromboxane    granted    mid    pulmonary    modifying    global    protecting    155    urgent    trial    2025    share    platform    ema    designation    market    patents    hope    drug    lower    evaluations    serious    treating    atxa    2033    payors    clinical    carry    scaled    size    hypertension    orphan    marketing    trials    capture    position    human    starting    models    blockbuster    imminent    disease    poorly    sme    authorization    cta    medicines    fits    employees    demand    lung    ltd    arterial    lucrative    agencies    expectancy    life    ntp42    launch    tolerated    fda    ambition    patients    preclinical    healthcare    regulatory    securing    therapeutic    animal    ing    mission    drugs    pah    secured    receptor   

Project "PAH-HOPE" data sheet

The following table provides information about the project.

Coordinator
ATXA THERAPEUTICS LTD 

Organization address
address: 75 AVOCA PARK AVOCA AVENUE BLACKROCK
city: DUBLIN
postcode: A94 N803
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Ireland [IE]
 Project website https://www.atxatherapeutics.com/pah-hope
 Total cost 3˙570˙000 €
 EC max contribution 2˙499˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2018
 Duration (year-month-day) from 2018-10-01   to  2020-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ATXA THERAPEUTICS LTD IE (DUBLIN) coordinator 2˙499˙000.00

Map

 Project objective

ATXA Therapeutics Ltd is a company on a mission to offer new hope to patients with pulmonary arterial hypertension (PAH). PAH is a debilitating lung & heart disease with an urgent need for new medicines targeting different pathways than current drugs. These drugs do not effectively treat the disease, they carry serious side-effects, are poorly tolerated and only extend life-expectancy from 2.8 years (untreated) to 3.6 years (treated). ATXA has developed novel therapeutic drugs to treat PAH. ATXA’s drug target is the human Thromboxane Receptor, a pathway involved in all the clinical features of PAH. Based on evaluations in 2 independent animal models of PAH, ATXA’s lead NTP42 is predicted to be a truly disruptive disease-modifying drug, treating all aspects of PAH and greatly extending life expectancy. ATXA has completed the preclinical phase of its drug development program and has secured orphan designation from the EMA and FDA regulatory agencies for NTP42 for PAH treatment. The objective of PAH-HOPE is to advance ATXA’s drug NTP42 into clinical development, starting from scaled up drug manufacture through to securing regulatory clinical trial authorization (CTA). Securement of CTA will position ATXA to advance NTP42 to Phase I-III clinical trials through to marketing authorization and product launch in 2025. ATXA’s NTP42 fits with the current focus on value-based healthcare delivery, resulting in improved healthcare outcomes that matter to patients, physicians, payors but at lower cost of delivery. ATXA’s ambition is that NTP42 will capture 15% share of the lucrative PAH market resulting in $700m revenue within five years following global commercialization, growing to a mid-size SME with 155 employees. ATXA has 8 granted patents protecting NTP42 out to 2033 and beyond, which will address the imminent patent cliff of current PAH drugs. Moreover, ATXA’s NTP42 has platform applications in several other disease areas with blockbuster demand & market potential.

 Publications

year authors and title journal last update
List of publications.
2019 T Kinsella, E Mulvaney, HM Reid
Efficacy of the novel thromboxane receptor antagonist NTP42 alone, or in combination with Sildenafil, in the sugen/hypoxia-induced model of pulmonary arterial hypertension
published pages: , ISSN: , DOI:
European Journal of Cardiology 40 2019-10-07
2019 T Kinsella, E Mulvaney, HM Reid
NTP42, an antagonist of the thromboxane receptor, attenuates experimentally-induced pulmonary arterial hypertension
published pages: , ISSN: , DOI:
European Respiratory Journal 2019-10-07
2019 Eamon P. Mulvaney, Áine G. O\'Sullivan, Sarah B. Eivers, Helen M. Reid, B. Therese Kinsella
Differential expression of the TPα and TPβ isoforms of the human T Prostanoid receptor during chronic inflammation of the prostate: Role for FOXP1 in the transcriptional regulation of TPβ during monocyte-macrophage differentiation
published pages: 104277, ISSN: 0014-4800, DOI: 10.1016/j.yexmp.2019.104277
Experimental and Molecular Pathology 110 2019-08-30

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PAH-HOPE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PAH-HOPE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More  

HAC (2019)

ADVANCED TREATMENT OF CONTAMINATED SOIL

Read More  

DeltaQon (2019)

IOT and cloud computing for online medical analysis service platform

Read More